Provided By GlobeNewswire
Last update: Jun 20, 2025
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation
Read more at globenewswire.com7.16
-0.23 (-3.11%)
Find more stocks in the Stock Screener